Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701182 | European Journal of Surgical Oncology (EJSO) | 2016 | 11 Pages |
Abstract
Although adverse patient and tumor characteristics were not equally balanced between treatment arms, our systematic review and meta-analysis supports similar oncological outcomes between SU and RNU, with better preservation of renal function after SU. As such, SU should be preferably used as the first-line treatment for low-risk ureter tumors, while considered for selected cases of high-risk disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D. Fang, T. Seisen, K. Yang, P. Liu, X. Fan, N. Singla, G. Xiong, L. Zhang, X. Li, L. Zhou,